Conferences - Results from #920

Viewing 921-940 of 11745 articles

ASCO GU 2024: Punch: Preliminary Results from a Phase II Study of Intra‑arterial Chemotherapy Combined with Tislelizumab and BCG in High-Risk Non-Muscle-Invasive Bladder Cancer

ASCO GU 2024: SAKK 06/19 - Intravesical Recombinant BCG Followed by Perioperative Chemo-Immunotherapy for Patients with Muscle-Invasive Bladder Cancer: A Multicenter, Single Arm Phase 2 Trial

ASCO GU 2024: MAIN-CAV: Phase III Randomized Trial of Maintenance Cabozantinib and Avelumab vs Avelumab After First-Line Platinum-Based Chemotherapy in Patients with Metastatic Urothelial Cancer

ASCO GU 2024: Adverse Effects and Discontinuation of Pembrolizumab in BCG Refractory Non-Muscle Invasive Bladder Cancer

ASCO GU 2024: Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Long-Term Patient-Reported Outcomes in the Phase 3 JAVELIN Bladder 100 Trial

ASCO GU 2024: ABLE-41: Nadofaragene Firadenovec-Vncg Early Use and Outcomes in a Real-World Setting in the United States

ASCO GU 2024: Economic Burden of Radical Cystectomy and Trimodal Therapy for Bladder Cancer in the United States: Real-World Study

ASCO GU 2024: Urine-Based Testing for Patient Selection and Genomic Characterization of Patients with FGFR Alteration-Positive NMIBC Treated with TAR-210

ASCO GU 2024: Updated Results from AVENANCE: Real-World Effectiveness of Avelumab First-Line Maintenance in Patients with Advanced Urothelial Carcinoma and Analysis of Subsequent Treatment

ASCO GU 2024: Defining Molecular Features Associated with Microsatellite Instability and Response to Immune Checkpoint Blockade in Urothelial Carcinoma

ASCO GU 2024: FGFR3 Mutated Urothelial Carcinoma of Bladder or Upper Tract: A Comparative Genomic Landscape Study

ASCO GU 2024: Oral APL-1202 in Combination with Tislelizumab as Neoadjuvant Therapy in Patients with MIBC: Interim Analysis of ANTICIPATE Phase II Trial

ASCO GU 2024: Urachal and Non-urachal Adenocarcinomas of the Bladder: A Comparative Comprehensive Genomic Profiling Study

ASCO GU 2024: Predictive Value of Dynamic Changes in ctDNA and Baseline Biomarkers with Neoadjuvant Atezolizumab in Operable Urothelial Carcinoma in the ABACUS Trial

ASCO GU 2024: Safety and Efficacy of Enfortumab Vedotin in Patients with Metastatic/locally Advanced Urothelial Cancer: Real-World Evidence from a European Database

ASCO GU 2024: Optimizing Treatment Strategies for Patients with Positive Pelvic/Retroperitoneal Lymph Nodes – Complete Clinical Response: Now What?

ASCO GU 2024: Outcomes in Patients with Advanced Urothelial Carcinoma Treated with Enfortumab Vedotin After Switch Maintenance Avelumab in the UNITE Study

ASCO GU 2024: HER2 and PD-L1 Immunohistochemistry Expression, and HER2 Genomic Alterations: Associations and Clinical Outcomes for Advanced Bladder Cancer

ASCO GU 2024: A Phase 2 Single-Arm Study Testing SBRT, Adenosine Signaling Modulation, and Immune Checkpoint Inhibition for Men with Hormone-Sensitive Oligometastatic Prostate Cancer (SBRT-AMICO)

ASCO GU 2024: Apalutamide plus Intermittent Versus Continuous Androgen-Deprivation Therapy in Participants with Metastatic Castration-Sensitive Prostate Cancer: LIBERTAS Phase 3 Study Design

42
43
44
45
46
47
48
49
50
51